Apararenone (MT-3995) 是新型非甾体类盐皮质激素受体 (mineralocorticoid receptor) 拮抗剂，正在开发用于研究糖尿病性肾病和非酒精性脂肪性肝炎。
| 生物活性 |
Apararenone (MT-3995) is a novel non-steroidal mineralocorticoid receptor antagonists under development for the treatment of diabetic nephropathies and non-alcoholic steatohepatitis. |
||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 体内研究 |
Recently, a phase II clinical trial has been initiated among patients with non-alcoholic steatohepatitis (NASH) in Japan.
|
||||||||||||||||
| 分子量 |
364.39
|
||||||||||||||||
| CAS号 |
945966-46-1
|
||||||||||||||||
| 运输条件 |
Room temperature in continental US; may vary elsewhere. |
||||||||||||||||
| 储存方式 |
|
||||||||||||||||
| 溶解性数据 |
In Vitro:
DMSO : ≥ 125 mg/mL (343.04 mM) * "≥" means soluble, but saturation unknown. 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 |
||||||||||||||||
| 临床试验 |
|
纯度： 98%
关注我们
获得KKL MED 最新资讯
咨询热线：
400-881-9290
Data Sheet